Sustained improvement in rheumatoid arthritis following a protocol designed to deplete B lymphocytes - PubMed (original) (raw)
Clinical Trial
Sustained improvement in rheumatoid arthritis following a protocol designed to deplete B lymphocytes
J C Edwards et al. Rheumatology (Oxford). 2001 Feb.
Abstract
Objectives: An open study of B-lymphocyte depletion was undertaken in rheumatoid arthritis (RA) patients to test the hypothesis that B lymphocytes may be essential to disease perpetuation.
Methods: Five patients with refractory RA were treated with a monoclonal anti-CD20 antibody, cyclophosphamide and prednisolone and followed for 12-17 months. Patient 2 received further treatments at 8 and 12 months and patient 4 at 11 months.
Results: At 26 weeks all patients satisfied the American College of Rheumatology ACR50 and patients 1-3 the ACR70 criteria of improvement, without further therapy. Patients 1, 3 and 5 achieved ACR70 at 1 yr and rheumatoid factor (RF) levels fell to normal. In patients 3 and 5, B lymphocytes returned without relapse. Patient 2 relapsed at 28 weeks and patient 4 at 38 weeks, coincident with the return of B lymphocytes in the presence of raised RF levels. Both achieved ACR70 on retreatment. Adverse events were limited to respiratory episodes (two patients) and marginal thrombocytopenia (one patient).
Conclusions: These findings are consistent with the concept that RA is critically dependent on B lymphocytes and suggest that B-lymphocyte depletion may be a safe and effective therapy.
Similar articles
- Serologic changes following B lymphocyte depletion therapy for rheumatoid arthritis.
Cambridge G, Leandro MJ, Edwards JC, Ehrenstein MR, Salden M, Bodman-Smith M, Webster AD. Cambridge G, et al. Arthritis Rheum. 2003 Aug;48(8):2146-54. doi: 10.1002/art.11181. Arthritis Rheum. 2003. PMID: 12905467 - Clinical outcome in 22 patients with rheumatoid arthritis treated with B lymphocyte depletion.
Leandro MJ, Edwards JC, Cambridge G. Leandro MJ, et al. Ann Rheum Dis. 2002 Oct;61(10):883-8. doi: 10.1136/ard.61.10.883. Ann Rheum Dis. 2002. PMID: 12228157 Free PMC article. Clinical Trial. - B lymphocyte depletion in rheumatoid arthritis: targeting of CD20.
Edwards JC, Leandro MJ, Cambridge G. Edwards JC, et al. Curr Dir Autoimmun. 2005;8:175-92. doi: 10.1159/000082103. Curr Dir Autoimmun. 2005. PMID: 15564721 Clinical Trial. - Infliximab and methotrexate in the treatment of rheumatoid arthritis: a systematic review and meta-analysis of dosage regimens.
Zintzaras E, Dahabreh IJ, Giannouli S, Voulgarelis M, Moutsopoulos HM. Zintzaras E, et al. Clin Ther. 2008 Nov;30(11):1939-55. doi: 10.1016/j.clinthera.2008.11.007. Clin Ther. 2008. PMID: 19108784 Review. - B cells in rheumatoid arthritis: from hypothesis to the clinic.
Keystone EC. Keystone EC. Rheumatology (Oxford). 2005 May;44 Suppl 2:ii8-ii12. doi: 10.1093/rheumatology/keh617. Rheumatology (Oxford). 2005. PMID: 15851525 Review.
Cited by
- Progress of rituximab in the treatment of systemic lupus erythematosus and lupus nephritis.
Mo S, Li Y, He J, Lin L. Mo S, et al. Front Med (Lausanne). 2024 Oct 4;11:1472019. doi: 10.3389/fmed.2024.1472019. eCollection 2024. Front Med (Lausanne). 2024. PMID: 39430591 Free PMC article. Review. - Synthetically glycosylated antigens for the antigen-specific suppression of established immune responses.
Tremain AC, Wallace RP, Lorentz KM, Thornley TB, Antane JT, Raczy MR, Reda JW, Alpar AT, Slezak AJ, Watkins EA, Maulloo CD, Budina E, Solanki A, Nguyen M, Bischoff DJ, Harrington JL, Mishra R, Conley GP, Marlin R, Dereuddre-Bosquet N, Gallouët AS, LeGrand R, Wilson DS, Kontos S, Hubbell JA. Tremain AC, et al. Nat Biomed Eng. 2023 Sep;7(9):1142-1155. doi: 10.1038/s41551-023-01086-2. Epub 2023 Sep 7. Nat Biomed Eng. 2023. PMID: 37679570 - Promising Experimental Treatments for Lupus Nephritis: Key Talking Points and Potential Opportunities.
Neves A, Viveiros L, Venturelli V, Isenberg DA. Neves A, et al. Res Rep Urol. 2023 Jul 10;15:333-353. doi: 10.2147/RRU.S385836. eCollection 2023. Res Rep Urol. 2023. PMID: 37456804 Free PMC article. Review. - Targeted Therapy for SLE-What Works, What Doesn't, What's Next.
Venturelli V, Isenberg DA. Venturelli V, et al. J Clin Med. 2023 Apr 29;12(9):3198. doi: 10.3390/jcm12093198. J Clin Med. 2023. PMID: 37176637 Free PMC article. Review. - Pathogenesis and treatment of Sjogren's syndrome: Review and update.
Zhan Q, Zhang J, Lin Y, Chen W, Fan X, Zhang D. Zhan Q, et al. Front Immunol. 2023 Feb 2;14:1127417. doi: 10.3389/fimmu.2023.1127417. eCollection 2023. Front Immunol. 2023. PMID: 36817420 Free PMC article. Review.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical